ToR Approved for Sigachi's New Andhra Pradesh API Facility.

Sigachi Industries Limited, a prominent manufacturer of pharmaceutical excipients and active ingredients, has announced a significant step forward in its expansion plans, having received the Terms of Reference (ToR) from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh. This crucial approval paves the way for the development of its upcoming Bulk Drugs, Drug Intermediates, and Specialty Chemicals manufacturing facility in Orvakal, Kurnool District.

The strategic project is planned to span 25.09 acres at Plot No. A-10, Guttapadu-Orvakal Node. Classified under Category B1, the facility aligns with Schedule 5(f) of the Environmental Impact Assessment (EIA) Notification, 2006, which pertains to the Synthetic Organic Chemicals sector.

With the ToR now secured, the next phase, the Environmental Clearance (EC) process, is slated to commence from July 15, 2025. This will be swiftly followed by the initiation of project development activities from August 1, 2025.

The new facility is poised to be instrumental in several key areas for Sigachi Industries:

• Enhancing API Manufacturing and Global Reach: The project will significantly boost the company's capacity for Active Pharmaceutical Ingredients (APIs), enabling it to expand its presence in global markets.


• Pipeline Expansion: It will support the growth of Sigachi's product pipeline for both regulated and semi-regulated markets worldwide.


• Strategic Location with Export Potential: The facility's location in Orvakal is strategically chosen to maximize its export capabilities.


• Contribution to "Make in India": The project aligns with the national "Make in India" initiative, featuring world-class infrastructure and a commitment to sustainable manufacturing practices.

Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, expressed his enthusiasm regarding the development: "This is a significant milestone in our journey to become a vertically integrated pharmaceutical manufacturing company. The Orvakal project will anchor our next phase of growth in APIs and specialty chemicals, helping us create scalable, sustainable, and compliant operations for global markets."

Sinha further emphasized the strategic rationale behind the expansion, stating, "At Sigachi, we are strategically positioning ourselves to cater to increasing global demand by building capacity closer to key markets and regulatory jurisdictions. The new facility will not only strengthen our product supply chain but also enable faster commercialization, seamless tech transfers, and enhanced responsiveness to evolving customer requirements."